InspireMD Amends Series J, K Warrants, Eyes Up to $11M Ahead of CGuard Prime FDA Decision

InspireMD Inc. (NSPR) amended certain outstanding Series J and Series K warrants, a move that could raise up to $11 million in gross proceeds if the warrants are fully exercised, the company said on September 21, 2026. The warrant amendments are tied to the anticipated U.S. Food and Drug Administration decision on the company's CGuard Prime carotid stent system. InspireMD did not disclose revised exercise prices or expiration terms in the announcement. The company expects the changes to align warrant holders with the pending regulatory milestone. Full exercise of the warrants would provide additional capital as InspireMD prepares for a potential U.S. commercial launch of CGuard Prime.